Xiao-qing-long-tang ameliorates OVA-induced allergic rhinitis by inhibiting ILC2s through the IL-33/ST2 and JAK/STAT pathways
Phytomedicine · 2023
DOI: 10.1016/j.phymed.2023.155012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2023. Verfasst von Jia-Jun Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Department of Otorhinolaryngology, the Seco…. Hauptthemen laut MEDLINE: Immunity, Innate, Rhinitis, Allergic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa that is mediated by immunoglobulin E (IgE). Xiao-qing-long-tang (XQLT) is a traditional Chinese medicine compound that is widely used to treat respiratory diseases such as AR. However, the underlying mechanism of the effect of XQLT on AR remains unclear. PURPOSE: To elucidate the effect of XQLT on ovalbumin (OVA)-induced AR and the mechanisms of action. METHODS: The therapeutic efficacy of XQLT was evaluated in a well-established OVA-induced AR mouse model. Nasal symptoms were analyzed, type 2 cytokines and OVA-sIgE levels were measured, nasal mucosa tissues were collected for histological analysis, and the changes of Group 2 innate lymphoid cells (ILC2s) and the IL-33/ST2 and JAK/STAT signaling pathways in the nasal mucosa were observed. RESULTS: XQLT significantly alleviated the nasal symptoms and histological damage to the nasal mucosa in AR mice, and reduced the levels of type 2 cytokines and OVA-sIgE. In addition, after XQLT treatment, the numbers of ILC2s in the nasal mucosa of AR mice were reduced, and the mRNA levels of the transcription factors GATA3 and ROR-α were decreased. Moreover, IL-33/ST2 signaling pathway was inhibited. The costimulatory cytokine associated JAK/STAT signaling pathway was also inhibited in ILC2s. CONCLUSION: Our study demonstrated that XQLT regulated ILC2s through the IL-33/ST2 and JAK/STAT pathways to ameliorate type 2 inflammation in OVA-induced AR. These findings suggest that XQLT might be used to treat AR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Department of Otorhinolaryngology, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern…
- The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
- Otorhinolaryngology Department, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
- Otorhinolaryngology Department, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, 510405, China. Ele…
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J. J., He, X. C., Zhou, M., Liu, Q. D., Xu, W. Z., Yan, Y. J., & Ruan, Y. (2023). Xiao-qing-long-tang ameliorates OVA-induced allergic rhinitis by inhibiting ILC2s through the IL-33/ST2 and JAK/STAT pathways. Phytomedicine. https://doi.org/10.1016/j.phymed.2023.155012
Vancouver
Zhang JJ, He XC, Zhou M, Liu QD, Xu WZ, Yan YJ, et al. Xiao-qing-long-tang ameliorates OVA-induced allergic rhinitis by inhibiting ILC2s through the IL-33/ST2 and JAK/STAT pathways. Phytomedicine. 2023. doi:10.1016/j.phymed.2023.155012
BibTeX
@article{Zhang2023,
author = {Zhang, Jia-Jun and He, Xue-Cheng and Zhou, Min and Liu, Qin-Dong and Xu, Wei-Zhen and Yan, Ya-Jie and Ruan, Yan},
title = {Xiao-qing-long-tang ameliorates OVA-induced allergic rhinitis by inhibiting ILC2s through the IL-33/ST2 and JAK/STAT pathways},
journal = {Phytomedicine},
year = {2023},
doi = {10.1016/j.phymed.2023.155012}
}
EUVIMED